Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Chihiro K, Kawaoka T, Uchikawa S, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Amioka K, Naruto K, Ando Y, Yamaoka K, Teraoka Y, Uchida T, Fujino H, Nakahara T, Ono A, Murakami E, Okamoto W, Yamauchi M, Miki D, Tsuge M, Imamura M, Aikata H, Oka S. Chihiro K, et al. Among authors: johira y. Oncology. 2023;101(8):491-501. doi: 10.1159/000530991. Epub 2023 Jul 10. Oncology. 2023. PMID: 37429266
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H. Ando Y, et al. Among authors: johira y. Cancers (Basel). 2021 Aug 5;13(16):3958. doi: 10.3390/cancers13163958. Cancers (Basel). 2021. PMID: 34439111 Free PMC article.
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S, Kawaoka T, Johira Y, Miura R, Kosaka M, Shirane Y, Murakami S, Amioka K, Naruto K, Ando Y, Kosaka Y, Yamaoka K, Kodama K, Uchikawa S, Fujino H, Ohno A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori K, Arihiro K, Kuroda S, Kobayashi T, Ohdan H, Aikata H. Yano S, et al. Among authors: johira y. Medicine (Baltimore). 2021 Oct 22;100(42):e27576. doi: 10.1097/MD.0000000000027576. Medicine (Baltimore). 2021. PMID: 34678902 Free PMC article.
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
Yamaoka K, Kodama K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Yano S, Murakami S, Amioka K, Naruto K, Ando Y, Kosaka Y, Uchikawa S, Uchida T, Fujino H, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Miki D, Imamura M, Takahashi S, Nagao A, Chayama K, Aikata H. Yamaoka K, et al. Among authors: johira y. PLoS One. 2022 Jan 18;17(1):e0262675. doi: 10.1371/journal.pone.0262675. eCollection 2022. PLoS One. 2022. PMID: 35041693 Free PMC article.
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Murakami S, Yano S, Naruto K, Ando Y, Kosaka Y, Fujii Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Moriya T, Naeshiro N, Nonaka M, Hyogo H, Aisaka Y, Azakami T, Hiramatsu A, Aikata H. Amioka K, et al. Among authors: johira y. Cancers (Basel). 2022 Jan 10;14(2):320. doi: 10.3390/cancers14020320. Cancers (Basel). 2022. PMID: 35053484 Free PMC article.
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
Miura R, Kawaoka T, Imamura M, Kosaka M, Johira Y, Shirane Y, Murakami S, Yano S, Amioka K, Naruto K, Ando Y, Kosaka Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Hinoi T, Aikata H. Miura R, et al. Among authors: johira y. Case Rep Gastroenterol. 2022 Mar 4;16(1):110-115. doi: 10.1159/000522145. eCollection 2022 Jan-Apr. Case Rep Gastroenterol. 2022. PMID: 35431768 Free PMC article.
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Johira Y, Kawaoka T, Kosaka M, Shirane Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Ando Y, Kosaka Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Sentani K, Oue N, Arihiro K, Kuroda S, Kobayashi T, Ohdan H, Chayama K, Aikata H. Johira Y, et al. Liver Cancer. 2021 Nov 15;11(2):174-177. doi: 10.1159/000520898. eCollection 2022 Apr. Liver Cancer. 2021. PMID: 35634428 Free PMC article. No abstract available.
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
Kodama K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Yano S, Murakami S, Amioka K, Naruto K, Ando Y, Kosaka Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Miki D, Imamura M, Kuroda S, Kobayashi T, Ohdan H, Aikata H, Chayama K. Kodama K, et al. Among authors: johira y. J Gastroenterol. 2022 Sep;57(9):676-683. doi: 10.1007/s00535-022-01887-3. Epub 2022 Jul 18. J Gastroenterol. 2022. PMID: 35849192
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Naruto K, Ando Y, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Morio K, Moriya T, Naeshiro N, Nonaka M, Aisaka Y, Azakami T, Hiramatsu A, Aikata H, Oka S. Amioka K, et al. Among authors: johira y. Cancers (Basel). 2022 Oct 16;14(20):5066. doi: 10.3390/cancers14205066. Cancers (Basel). 2022. PMID: 36291850 Free PMC article.
20 results